- Home
- ZBAO vs NRXP Comparison
ZBAO vs NRXP Comparison
Compare ZBAO & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZBAO
- NRXP
- Stock Information
- Founded
- ZBAO 2015
- NRXP 2015
- Country
- ZBAO China
- NRXP United States
- Employees
- ZBAO N/A
- NRXP N/A
- Industry
- ZBAO
- NRXP Biotechnology: Pharmaceutical Preparations
- Sector
- ZBAO
- NRXP Health Care
- Exchange
- ZBAO NYSE
- NRXP Nasdaq
- Market Cap
- ZBAO 36.2M
- NRXP 32.6M
- IPO Year
- ZBAO 2024
- NRXP N/A
- Fundamental
- Price
- ZBAO $1.12
- NRXP $2.29
- Analyst Decision
- ZBAO
- NRXP Strong Buy
- Analyst Count
- ZBAO 0
- NRXP 4
- Target Price
- ZBAO N/A
- NRXP $28.50
- AVG Volume (30 Days)
- ZBAO 349.0K
- NRXP 184.4K
- Earning Date
- ZBAO 04-15-2025
- NRXP 05-15-2025
- Dividend Yield
- ZBAO N/A
- NRXP N/A
- EPS Growth
- ZBAO N/A
- NRXP N/A
- EPS
- ZBAO 0.09
- NRXP N/A
- Revenue
- ZBAO $33,673,520.00
- NRXP N/A
- Revenue This Year
- ZBAO $65.08
- NRXP N/A
- Revenue Next Year
- ZBAO $34.27
- NRXP N/A
- P/E Ratio
- ZBAO $12.24
- NRXP N/A
- Revenue Growth
- ZBAO 82.66
- NRXP N/A
- 52 Week Low
- ZBAO $0.85
- NRXP $1.10
- 52 Week High
- ZBAO $5.70
- NRXP $6.01
- Technical
- Relative Strength Index (RSI)
- ZBAO N/A
- NRXP 63.76
- Support Level
- ZBAO N/A
- NRXP $1.97
- Resistance Level
- ZBAO N/A
- NRXP $2.14
- Average True Range (ATR)
- ZBAO 0.00
- NRXP 0.12
- MACD
- ZBAO 0.00
- NRXP 0.03
- Stochastic Oscillator
- ZBAO 0.00
- NRXP 86.52
About ZBAO ZHIBAO TECHNOLOGY INC
Zhibao Technology Inc is a insurance technology company engaged in providing digital insurance brokerage services in China. 2B2C digital embedded insurance is their business model which is pioneered in China. It provides customized digital insurance solutions for B-side channels (covering a wide range of industries and organizations, including but not limited to Internet platforms, large and medium-sized enterprises, and government agencies, etc.), embedding them into the channel's existing business matrix, and providing the channel with Provide digital insurance brokerage services to C-end customers.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.